药物洗脱支架：人体研究和动物研究具有可比性吗？
Drug eluting stents: are human and animal studies comparable?
作者信息
Virmani R, Kolodgie F D, Farb A, Lafont A
机构信息
Department of Cardiovascular Pathology, Armed Forces Institute of Pathology, Washington DC 20306-6000, USA.
出版信息
Heart. 2003 Feb;89(2):133-8. doi: 10.1136/heart.89.2.133.
Abstract
Animal models of stenting probably predict human responses as the stages of healing are remarkably similar. What is characteristically different is the temporal response to healing, which is substantially prolonged in humans. The prevention of restenosis in recent clinical trials of drug eluting stents may represent a near absent or incomplete phase of intimal healing. Continued long term follow up of patients with drug eluting stents for major adverse cardiac events and angiographic restenosis is therefore imperative.
摘要
由于愈合阶段非常相似，支架置入的动物模型可能预测人类的反应。典型的不同之处在于对愈合的时间反应，这在人类中显著延长。药物洗脱支架近期临床试验中对再狭窄的预防可能代表内膜愈合几乎不存在或不完整的阶段。因此，对药物洗脱支架患者进行长期随访以观察主要不良心脏事件和血管造影再狭窄情况势在必行。
相似文献
1
Drug eluting stents: are human and animal studies comparable?
Heart. 2003 Feb;89(2):133-8. doi: 10.1136/heart.89.2.133.
3
Comparison between catheter-based delivery of paclitaxel after bare-metal stenting and drug-eluting stents in coronary artery disease patients at high risk for in-stent restenosis.
Cardiovasc Revasc Med. 2017 Dec;18(8):596-600. doi: 10.1016/j.carrev.2017.05.018. Epub 2017 May 31.
4
Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial.
JAMA. 2006 Mar 15;295(11):1253-63. doi: 10.1001/jama.295.11.1253. Epub 2006 Mar 12.
5
Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial.
JAMA. 2006 Mar 15;295(11):1264-73. doi: 10.1001/jama.295.11.1264. Epub 2006 Mar 12.
6
Drug-eluting stents: new era and new concerns.
Postgrad Med J. 2004 Jan;80(939):13-8. doi: 10.1136/pmj.2003.009431.
7
Drug-eluting stents: results, promises and problems.
Int J Cardiol. 2005 Mar 10;99(1):9-17. doi: 10.1016/j.ijcard.2004.01.021.
8
Comparative healing response after sirolimus- and paclitaxel-eluting stent implantation in a pig model of restenosis.
Catheter Cardiovasc Interv. 2009 May 1;73(6):801-8. doi: 10.1002/ccd.21879.
9
Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial.
JAMA. 2004 Dec 8;292(22):2727-34. doi: 10.1001/jama.292.22.2727.
10
Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial.
JAMA. 2006 Feb 22;295(8):895-904. doi: 10.1001/jama.295.8.895.
引用本文的文献
1
Ultrathin-strut versus thin-strut stent healing and outcomes in preclinical and clinical subjects.
EuroIntervention. 2024 May 20;20(10):e669-e680. doi: 10.4244/EIJ-D-23-00563.
2
Cardiovascular Tissue Engineering Models for Atherosclerosis Treatment Development.
Bioengineering (Basel). 2023 Nov 29;10(12):1373. doi: 10.3390/bioengineering10121373.
3
Faster smooth muscle cell coverage in ultrathin-strut drug-eluting stent leads to earlier re-endothelialization.
Front Bioeng Biotechnol. 2023 May 23;11:1207858. doi: 10.3389/fbioe.2023.1207858. eCollection 2023.
4
Assessment of Nit-Occlud atrial septal defect occluder device healing process using micro-computed tomography imaging.
PLoS One. 2023 Apr 24;18(4):e0284471. doi: 10.1371/journal.pone.0284471. eCollection 2023.
5
Early vascular responses to abluminal biodegradable polymer-coated versus circumferential durable polymer-coated newer-generation drug-eluting stents in humans: a pathological study.
EuroIntervention. 2023 Mar 20;18(15):1284-1294. doi: 10.4244/EIJ-D-22-00650.
6
What are the Pathological Concerns and Limitations of Current Drug-coated Balloon Technology?
Heart Int. 2019 Oct 11;13(1):15-22. doi: 10.17925/HI.2019.13.1.15. eCollection 2019.
7
Peri-interventional Triple Therapy With Dabigatran Improves Vasomotion and Promotes Endothelialization in Porcine Coronary Stenting Model.
Front Cardiovasc Med. 2021 Jul 2;8:690476. doi: 10.3389/fcvm.2021.690476. eCollection 2021.
8
Late neointimal volume reduction is observed following biodegradable polymer-based drug eluting stent in porcine model.
Int J Cardiol Heart Vasc. 2021 May 11;34:100792. doi: 10.1016/j.ijcha.2021.100792. eCollection 2021 Jun.
9
Effects of electret coating technology on coronary stent thrombogenicity.
Platelets. 2022 Feb 17;33(2):312-319. doi: 10.1080/09537104.2021.1912313. Epub 2021 Apr 15.
10
The antiplatelet agent revacept prevents the increase of systemic thromboxane A biosynthesis and neointima hyperplasia.
Sci Rep. 2020 Dec 8;10(1):21420. doi: 10.1038/s41598-020-77934-x.
本文引用的文献
1
Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL (RAndomized study with the sirolimus-eluting VElocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) trial.
Circulation. 2002 Aug 13;106(7):798-803. doi: 10.1161/01.cir.0000025585.63486.59.
2
Twenty-eight-day efficacy and phamacokinetics of the sirolimus-eluting stent.
Coron Artery Dis. 2002 May;13(3):183-8. doi: 10.1097/00019501-200205000-00008.
3
Morphological predictors of restenosis after coronary stenting in humans.
Circulation. 2002 Jun 25;105(25):2974-80. doi: 10.1161/01.cir.0000019071.72887.bd.
4
A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.
N Engl J Med. 2002 Jun 6;346(23):1773-80. doi: 10.1056/NEJMoa012843.
5
First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis: immediate and long-term clinical and angiographic outcome.
Circulation. 2002 Apr 23;105(16):1883-6. doi: 10.1161/01.cir.0000016042.69606.61.
6
Age and growth factors in porcine full-thickness wound healing.
Wound Repair Regen. 2001 Sep-Oct;9(5):371-7. doi: 10.1046/j.1524-475x.2001.00371.x.
7
Intracoronary beta-radiation of de novo coronary lesions using a (186)Re liquid-filled balloon system: six-month results from a clinical feasibility study.
Catheter Cardiovasc Interv. 2002 Jan;55(1):28-36. doi: 10.1002/ccd.10043.
8
Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up.
Circulation. 2001 Oct 23;104(17):2007-11. doi: 10.1161/hc4201.098056.
9
Living the dream of no restenosis.
Circulation. 2001 Oct 23;104(17):1996-8.
10
Late acute thrombosis after paclitaxel eluting stent implantation.
Heart. 2001 Sep;86(3):262-4. doi: 10.1136/heart.86.3.262.
Zotero 插件